Registry-listed formulations

pibrentasvir · mesh:C000622691

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 5 studies. This list may not include all unresolved or historical entries.

ABT-530Registry intervention
Linked study entry; product equivalence not established
View study and source
ABT-530Registry intervention
Linked study entry; product equivalence not established
View study and source
ABT-530Registry intervention
Linked study entry; product equivalence not established
View study and source
ABT-530Registry intervention
Linked study entry; product equivalence not established
View study and source
ABT-530Registry intervention
Linked study entry; product equivalence not established
View study and source

Success Metrics

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

100%(5 trials)

Phase Distribution

Phase 2

50%

Phase 2/3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

3(60.0%)

Phase 2/3Combined phases

2(40.0%)

Highest Phase Reached

Phase 2/3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Other(1)

Detailed Status

Completed5

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Trials by Phase

Phase 23 (60.0%)

Phase 2/32 (40.0%)

Trials by Status

unknown117%

completed583%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_2_3

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

NCT02243293

completedphase_2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection

NCT02243280

completedphase_2

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

NCT01995071

completedphase_2_3

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

NCT02441283

unknown

Expanded Access to Glecaprevir/ Pibrentasvir

NCT03123965

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT02243293Phase 2/3

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

Completed

NCT02243280Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection

Completed

NCT01995071Phase 2

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Completed

NCT02441283Phase 2/3

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Completed

NCT03123965

Expanded Access to Glecaprevir/ Pibrentasvir

Unknown

NCT02068222Phase 2

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Completed

All 6 trials loaded

Drug Details

Intervention Type: Drug
Molecule Type: Small molecule
Total Trials: 6

External References

ChEMBL

CHEMBL3545123

Names & Codes

Research Codes

A-1325912.0ABT-530